Competitive intelligence on 
 small-molecule drugs and 
 the 90,000 global patents 
 covering them 

Start your free trial now

DrugPatentWatch Ultimate Plan Preview

Details for Generic Name: octreotide acetate

« Back to Dashboard

Summary for Generic Name: octreotide acetate

Tradenames:4
Patents:6
Applicants:8
NDAs:18
Drug Master File Entries: see list13
Suppliers: see list2
Therapeutic Class:Hormonal Agents, Suppressant (Pituitary)

Pharmacology for Ingredient: octreotide acetate

Clinical Trials for: octreotide acetate

Efficacy/Safety of Octreotide Acetate in Patients With Uncontrolled Acromegaly
Status: Completed Condition: Acromegaly

Study to Evaluate the Efficacy and Safety of Sandostatin LAR at High Dose or in Combination Either With GH-receptor Antagonist or Dopamine-agonist in Acromegalic Patients
Status: Completed Condition: Acromegaly

Cixutumumab, Everolimus, and Octreotide Acetate in Treating Patients With Advanced Low to Intermediate Grade Neuroendocrine Carcinoma
Status: Active, not recruiting Condition: Gastrin-Producing Neuroendocrine Tumor; Lung Carcinoid Tumor; Metastatic Gastrointestinal Neuroendocrine Tumor G1; Pancreatic Glucagonoma; Pancreatic Insulinoma; Pancreatic Polypeptide Tumor; Paraganglioma; Recurrent Gastrointestinal Neuroendocrine Tumor G1; Recurrent Merkel Cell Carcinoma; Recurrent Pancreatic Neuroendocrine Carcinoma; Regional Gastrointestinal Neuroendocrine Tumor G1; Somatostatin-Producing Neuroendocrine Tumor; Stage III Merkel Cell Carcinoma; Stage IV Merkel Cell Carcinoma; Thyroid Gland Medullary Carcinoma

Octreotide Acetate and Recombinant Interferon Alfa-2b or Bevacizumab in Treating Patients With Metastatic or Locally Advanced, High-Risk Neuroendocrine Tumor
Status: Active, not recruiting Condition: Neuroendocrine Carcinoma

Study Assessing the Efficacy and Safety of Octreotide Acetate in Patients With Acromegaly, With Micro or Macroadenomas
Status: Terminated Condition: Acromegaly

Ultrasound Guided Sandostatin LAR Injection in Acromegaly
Status: Recruiting Condition: Acromegaly

Octreotide Compared to Placebo in Patients With Inoperable Bowel Obstruction Due to Peritoneal Carcinomatosis
Status: Completed Condition: Peritoneal Neoplasms; Intestinal Obstruction; Carcinomatosis

Everolimus and Octreotide Acetate With or Without Bevacizumab in Treating Patients With Locally Advanced or Metastatic Pancreatic Neuroendocrine Tumors That Cannot Be Removed by Surgery
Status: Active, not recruiting Condition: Gastrin-Producing Neuroendocrine Tumor; Malignant Pancreatic Gastrinoma; Malignant Pancreatic Glucagonoma; Malignant Pancreatic Insulinoma; Malignant Pancreatic Somatostatinoma; Pancreatic Alpha Cell Adenoma; Pancreatic Beta Cell Adenoma; Pancreatic Delta Cell Adenoma; Pancreatic G-Cell Adenoma; Pancreatic Glucagonoma; Pancreatic Insulinoma; Pancreatic Polypeptide Tumor; Recurrent Pancreatic Carcinoma; Recurrent Pancreatic Neuroendocrine Carcinoma; Somatostatin-Producing Neuroendocrine Tumor; Stage III Pancreatic Cancer; Stage IV Pancreatic Cancer

RAD001 Plus Octreotide Depot in Metastatic or Unresectable Low Grade Neuroendocrine Carcinoma
Status: Completed Condition: Neuroendocrine Carcinoma; Islet Cell Carcinoma

Everolimus and Octreotide in Patients With Advanced Carcinoid Tumor
Status: Completed Condition: Carcinoid Tumor; Malignant Carcinoid Syndrome

Courtesy of ClinicalTrials.org
See more clinical trials for this drug
Glossary
Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Sun Pharm Inds
OCTREOTIDE ACETATE
octreotide acetate
INJECTABLE;INJECTION077373Aug 14, 2007RXNo<disabled><disabled>
Teva Pharms Usa
OCTREOTIDE ACETATE
octreotide acetate
INJECTABLE;INJECTION075959Nov 21, 2005RXNo<disabled><disabled>
Novartis
SANDOSTATIN LAR
octreotide acetate
INJECTABLE;INJECTION021008Nov 25, 1998RXYes5,688,530*PED<disabled>Y<disabled>
Fresenius Kabi Usa
OCTREOTIDE ACETATE
octreotide acetate
INJECTABLE;INJECTION077450Feb 10, 2006RXNo<disabled><disabled>
Novartis
SANDOSTATIN LAR
octreotide acetate
INJECTABLE;INJECTION021008Nov 25, 1998RXNo5,688,530*PED<disabled>Y<disabled>
This preview shows a limited data set
Subscribe for full access, or try a free trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

DrugPatentWatch Archives

You are viewing the current data set
Select a link below to view the archives:

 2000   2001   2002   2003   2004   2005   2006   2007   2008   2009   2010   2011   2012   2013   2014  

For more information try a free trial or see the plan comparison

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.

Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2015 thinkBiotech LLC
ISSN: 2162-2639

Preferred citation:

Friedman, Y. Location of pharmaceutical innovation: 2000–2009 Nature Reviews Drug Discovery 9, 835–836 (2010).

Connect with Social Media:

Follow DrugPatentWatch on Twitter
Connect with DrugPatentWatch on Linkedin
Drug Patents on LinkedIn
`abc